Lebanon, Virginia, appears in the account as both a rural community confronting opioid addiction and a point of influence in Virginia’s changing treatment system. The town’s Highpower clinic, established by Hughes Melton to serve underserved patients, became a model for expanding medication-assisted treatment; at the same time, Lebanon’s three Suboxone clinics and local concerns about misuse exposed the disputes that could accompany that expansion.

A rural treatment center

Hughes Melton set up practice in Lebanon in 2000 because he wanted to treat people who were underserved. Highpower, the Suboxone clinic he established there, later served as a model for Virginia’s efforts to widen medication-assisted treatment. Melton also took on a role in directing the state’s opioid response, linking the work of a rural clinic to a broader public-health effort.

The clinic was run with his wife, Sarah Melton, a pharmacy professor and statewide patient advocate. Highpower required urine screening and provided both group and individual counseling. The account presents these requirements as part of a more structured approach to buprenorphine care, rather than a system focused on dispensing medication alone.

Treatment access and state policy

The Meltons’ work extended beyond the clinic. Hughes Melton helped state officials broaden Medicaid reimbursement for treatment and include payment for required counseling and care coordination. Those changes were intended, in part, to encourage cash-only clinics to accept insurance, including Medicaid. Sarah Melton trained more than four thousand doctors about opioid risks and reported physicians for overprescribing them.

The pressures behind this work were substantial. Federal rules then limited MAT-certified doctors to treating one hundred patients at a time; the cap rose to 275 later that year. The account describes access as widening in Virginia by 2017, but also emphasizes how slowly new capacity reached many communities. Lebanon was therefore significant not simply as the home of one clinic, but as a base from which its physician helped shape statewide treatment and reimbursement policy.

Local concerns and contested treatment

Lebanon’s clinic model existed alongside suspicion of buprenorphine. Some rural patients described being prescribed more Suboxone than they needed, then selling part of their supply to pay for follow-up visits; others traded it for heroin or pills. Sarah Melton acknowledged that diversion and abuse were real concerns, while arguing that the naloxone in Suboxone made it a valuable medicine and that treatment should include close monitoring and counseling. She also distinguished Suboxone from Subutex, which lacks naloxone and, according to her account, was more vulnerable to misuse.

Local unease was visible in the Lebanon police chief’s criticism of the number of clinics in a town of roughly 3,400 people. His objection reflected a wider law-enforcement hostility toward Suboxone, while the Meltons’ clinic represented a contrasting effort to provide medication within a monitored treatment program. The disagreement was not merely about the presence of clinics: it concerned how to expand effective care without ignoring diversion, and how to avoid allowing concern about misuse to become a barrier to treatment.

Significance

Lebanon’s role in the narrative rests on this double position. Highpower offered a rural example of buprenorphine treatment organized around screening and counseling, while Hughes Melton carried lessons from that practice into Virginia’s policy response. Yet the disputes surrounding the medication show why access could not be measured by the existence of clinics alone: rules, reimbursement, provider capacity, and local trust all shaped whether treatment was reachable and acceptable. Lebanon thus stands at the intersection of a practical treatment effort and a broader struggle over how medication-assisted care should be delivered.